The future of immuno-oncology is evolving rapidly, driven by the remarkable promise of bispecific antibodies (bsAbs). These advanced therapeutics have transformative potential, simultaneously targeting two distinct antigens and significantly enhancing therapeutic efficacy compared to traditional treatments. But what precisely sets bispecific antibodies apart, and how can we fully harness and visualize their capabilities?
Introducing Portrai’s innovative solution, PortraiTARGET™ POR-PBPK-Bispecific.
What is PortraiTARGET™ POR-PBPK-Bispecific?
PortraiTARGET™ POR-PBPK is an AI-empowered solution combining spatial transcriptomics and physiologically-based pharmacokinetic modeling (PBPK). By leveraging detailed human-derived spatial biology datasets (50M+ cells from 2,000+ patients), our platform accurately predicts the tissue-level distribution and concentration of bispecific antibodies within the tumor microenvironment (TME).
This capability was clearly demonstrated with a PD-1/VEGF bispecific antibody, revealing an antibody exposure level up to 4.5 times greater than that achieved with traditional monospecific antibodies within the same tumor context.
Clinical validation — bsAbs vs combination monospecifics
Recent clinical trials comparing PD-1/VEGF bispecific antibodies to conventional monospecific antibody combinations have shown significantly improved therapeutic outcomes. Bispecific antibodies consistently demonstrate enhanced therapeutic efficacy, primarily due to their unique pharmacokinetic properties and targeted dual-binding capacity.
The PortraiTARGET™ platform has been instrumental in uncovering the underlying reasons for these superior results. By generating precise drug distribution maps within the TME, PortraiTARGET™ provides insights into differential accumulation patterns, cooperative binding dynamics, and systemic clearance differences. This detailed understanding clarifies why bispecific antibodies perform better than their monospecific counterparts.
Real-world insights, not just models
PortraiTARGET™ doesn’t simply rely on theoretical predictions. Instead, it combines cutting-edge AI models with validated, real-world spatial biology data. This powerful combination provides unparalleled accuracy in predicting the behavior of bispecific antibodies, reflecting the true complexities of human biology.
Enhanced efficacy through cooperative binding
How does cooperative binding specifically influence tumor treatment outcomes? Cooperative binding, where binding to one target enhances binding affinity to another, leads to significantly increased intratumoral drug distribution. PortraiTARGET™ has demonstrated this effect clearly, showing substantial improvements in drug distribution and predicted therapeutic efficacy.
A call for strategic collaboration
At Portrai, we’re dedicated to accelerating the development of groundbreaking therapeutics. We actively seek co-development and research partnerships with pharmaceutical leaders committed to innovation. Our platform offers partners a unique opportunity to:
- De-risk target selection and optimization for bispecific antibodies, T cell engagers, radiopharmaceuticals, and antibody-drug conjugates (ADCs).
- Validate therapeutic hypotheses using real-world, spatially-informed models.
- Accelerate drug development timelines by leveraging our AI-driven insights.
Together, we can harness the full potential of bispecific antibodies, T cell engagers, radiopharmaceuticals, and antibody-drug conjugates (ADCs), driving more effective treatments to patients faster.
